Effect of olanzapine in gastric cancer patients receiving chemotherapy

Effect of olanzapine on symptom- relief and quality of life in gastric cancer patients receiving chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015070822991N2

Enrollment

Registered

2016-02-01

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neoplasms. Malignant neoplasm of stomach

Interventions

Intervention 1: Intervention group will receive 5-10 milligram per day olanzapine tablet from one day before chemotherapy to 8 weeks after chemotherapy, besides routine chemotherapy medication. Interv

Treatment - Drugs

Intervention group will receive 5-10 milligram per day olanzapine tablet from one day before chemotherapy to 8 weeks after chemotherapy, besides routine chemotherapy medication.

Control group will receive only routine chemotherapy medication.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: gastric cancer patients whose disease diagnosed recently and candidate for chemotherapy; patient´s informed consent for participation in the study Exclusion criteria: history of severe psychiatric problems such as severe cognitive disorders, psychotic disorders, antipsychotic medication such as risperidone, clozapine, phenothiazine,… in 30 days before or duration of the protocol; history of severe neurologic diseases such as metastasis to the brain, convulsion, ...; mental retardation; serum creatinine level more than 2 milligram per deciliter; total serum bilirubin level more than 2 milligram per deciliter; hepatic enzymes more than three times higher than upper limit of normal range; neutrophil count less than 1500; pregnancy; uncontrolled cardiac diseases such as cardiac arrhythmias, heart failure, acute myocardial infarction in the last 6 months; uncontrolled diabetes mellitus

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: 4th and 8th week after initiation of chemotherapy. Method of measurement: with standard questionnaire of WHO- QOL- BREF.;Severity of depression and anxiety in the patient. Timepoint: 4th and 8th weeks after chemotherapy. Method of measurement: Hospital Anxiety and Depression Scale (HADS).	—

Secondary

Measure	Time frame
Nausea and Vomiting. Timepoint: before treatment to six days after chemotherapy. Method of measurement: Rhodes index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSussan Moudi, MD

Babol University of Medical Sciences

sussanmo@hotmail.com+98 11 3236 5683

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026